Non-confidential introduction – Myllia
At Myllia, we use the CROP-Seq technology to perturb cells with CRISPR and profile transcriptional outcomes by RNA sequencing at single-cell resolution.
“Every CRISPR screen is built to answer a decision-critical question.”
CRISPR screening has revolutionized the unbiased annotation of gene function, but most screens done so far have been confined to rather simplistic read-outs (usually life/death of the target cells). Combining CRISPR perturbation with single-cell sequencing allows researchers to assess much more complex phenotypes, thus effectively broadening the scope of these screens.
At Myllia, we combine primary human cell CRISPR screening with single-cell transcriptomics (CROP-Seq/Perturb-Seq) to unlock rich, high-content biological insights – a game-changing technology for drug target discovery with unprecedented depth, precision, and fidelity:
➜ Human-centric, disease-relevant primary cell models
➜ Proprietary algorithms for sgRNA library designs
➜ High-content phenotyping readouts, e.g., scRNA-Seq
➜ Advanced, fully integrated computational biology
➜ Scalable, single-cell perturbation datasets for AI/ML models
Download Myllia’s non-confidential introduction and explore our causal, mechanism-resolved target discovery platform including many functional, high-content read-outs!